Savara(US:SVRA) Globenewswire·2025-10-26 13:31Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Savara Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's Biologics License Application (BLA) for MOLBREEVI [4][6]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Savara between March 7, 2024, and May 23, 2025, to discuss their legal rights [1]. - There is a deadline of November 7, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Savara [4]. - The complaint alleges that Savara and its executives made false statements regarding the MOLBREEVI BLA, which lacked sufficient information for FDA approval [6]. Group 2: Stock Performance Impact - Following the announcement of a refusal to file letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price dropped by $0.90 per share, or 31.69%, closing at $1.94 per share on May 27, 2025 [7]. Group 3: Class Action Participation - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [8]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Savara's conduct [9].